News | June 03, 2022
Mitsubishi Tanabe Pharma America presents 48-week results from phase 3 safety clinical study of Radicava ORS
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
These and many other questions gather worldwide experts of the pharmaceutical industry at the PHARMAP 2022 which takes place in Berlin, Germany on June, 20 - 21, 2022
By 2025, Cipla plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry.
Focussed campaigns for old age homes, schools/colleges, prisons, brick kilns to be taken up by States/UTs
PAYBACK loyalty will be live in 4500 Apollo Pharmacy outlets across India
Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
This expansion announcement came right after raising series B funding of $27 Mn in a round led by Fundamentum Partnership, earlier this month.
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights how blockchain ensures the authenticity of products thereby, improves trust, traceability, and transparency across key sectors
Subscribe To Our Newsletter & Stay Updated
